Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06653153
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-21
Brief Title:
A Study of Remternetug in Early Alzheimers Disease
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Study of Remternetug Versus Placebo in Early Alzheimers Disease Participants at Risk for Cognitive and Functional Decline
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to measure the difference in time to developing or worsening memory thinking or functional problems due to Alzheimers disease occurring in participants receiving study drug compared to placebo
Participation could last up to 255 weeks including screening a double-blind treatment period and a double-blind observation period In addition eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period
Participation could last up to 255 weeks including screening a double-blind treatment period and a double-blind observation period In addition eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None